UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer

Breast cancer research : BCR, 2021-03, Vol.23 (1), p.40-40, Article 40

2021

Volltextzugriff (PDF)

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e003354

2021

Volltextzugriff (PDF)

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

Frontiers in immunology, 2019-11, Vol.10, p.2614-2614

2019

Volltextzugriff (PDF)

TLR3 Activation of Intratumoral CD103 + Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity

Frontiers in immunology, 2019-03, Vol.10, p.503-503

2019

Volltextzugriff (PDF)

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand

PloS one, 2015-10, Vol.10 (10), p.e0140672-e0140672

2015

Volltextzugriff (PDF)

Correction to: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer

Breast cancer research : BCR, 2021-04, Vol.23 (1), p.48-48, Article 48

2021

Volltextzugriff (PDF)

Downregulation of adaptor protein MyD88 compromises the angiogenic potential of B16 murine melanoma

PloS one, 2017-06, Vol.12 (6), p.e0179897-e0179897

2017

Volltextzugriff (PDF)

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

The Journal of clinical investigation, 2021-01, Vol.131 (2), p.1-10

2021

Volltextzugriff (PDF)

105 4–1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A115-A116

2021

Volltextzugriff (PDF)

Establishing an immunocompetent mouse model of CAR T anti-tumor efficacy for studies of therapeutic resistance

The Journal of immunology (1950), 2024-05, Vol.212 (1_Supplement), p.1393-1393_4955

2024

Volltextzugriff (PDF)

The length of the intracellular domain conditions the antitumor efficacy of CAR-T cells

The Journal of immunology (1950), 2020-05, Vol.204 (1_Supplement), p.170-170.20

2020

Volltextzugriff (PDF)

Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity

Proceedings of the National Academy of Sciences - PNAS, 2019-11, Vol.116 (48), p.24231-24241

2019

Volltextzugriff (PDF)

CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2019-12, Vol.33 (6), p.647-659

2019

Volltextzugriff (PDF)

Abstract 934: γδ CAR T-cell therapy significantly mitigates bone metastatic castrate-resistant prostate cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.934-934

2019

Volltextzugriff (PDF)

In Vivo Visualizing the IFN-β Response Required for Tumor Growth Control in a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration

The Journal of immunology (1950), 2016-03, Vol.196 (6), p.2860-2869

2016

Volltextzugriff (PDF)

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8.sup.+ T Cells upon Stimulation with a TLR7 Ligand

PloS one, 2015-10, Vol.10 (10)

2015

Volltextzugriff (PDF)

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

Science advances, 2023-05, Vol.9 (18), p.eadf0108-eadf0108

2023

Volltextzugriff (PDF)

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand: e0140672

PloS one, 2015-10, Vol.10 (10)

2015

Volltextzugriff (PDF)

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The lancet oncology, 2020-04, Vol.21 (4), p.497-507

2020

Volltextzugriff (PDF)

The new Italian seismic hazard model (MPS19)

Annals of geophysics, 2021-03, Vol.64 (1)

2021

Volltextzugriff (PDF)

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

TLR3 Activation of Intratumoral CD103 + Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand

Correction to: High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer

Downregulation of adaptor protein MyD88 compromises the angiogenic potential of B16 murine melanoma

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

105 4–1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells

Establishing an immunocompetent mouse model of CAR T anti-tumor efficacy for studies of therapeutic resistance

The length of the intracellular domain conditions the antitumor efficacy of CAR-T cells

Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity

CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms

Abstract 934: γδ CAR T-cell therapy significantly mitigates bone metastatic castrate-resistant prostate cancer

In Vivo Visualizing the IFN-β Response Required for Tumor Growth Control in a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8.sup.+ T Cells upon Stimulation with a TLR7 Ligand

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer

Aging Impairs the Ability of Conventional Dendritic Cells to Cross-Prime CD8+ T Cells upon Stimulation with a TLR7 Ligand: e0140672

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The new Italian seismic hazard model (MPS19)

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

Suchergebnisse filtern